|Bid||365.00 x 7471200|
|Ask||365.50 x 1676700|
|Day's Range||301.90 - 365.00|
|52 Week Range||185.30 - 1,208.00|
|Beta (5Y Monthly)||-0.20|
|PE Ratio (TTM)||2,134.50|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology that enables the functional selection of stem cells, today announced that its Board of Directors has approved, and the company has entered, subject to definitive agreements, into a commercial binding Letter Of Intent (LOI) with Canndoc Ltd, a leading pharma grade medical cannabis pioneer, a wholly owned subsidiary of publicly-traded Intercure Ltd. (TASE: INCR).
HERZLIYA, Israel, Nov. 21, 2019 /PRNewswire/ -- Israeli medical cannabis company InterCure Ltd. (TASE: INCR) announced that its wholly-owned subsidiary Canndoc initiated a phase 3 clinical trial with the Shamir Medical Center (Assaf HaRofeh) for the treatment of children with autism spectrum disorder. The program will be led by Dr. Orit Stoller, a pediatric neurologist at the Autism Center at Shamir (Assaf HaRofeh), and Prof. Mati Berkovitch, Head of the Clinical Pharmacology Unit at the Shamir Medical Center (Assaf HaRofeh), validating the safety and efficacy of Canndoc's GMP pharma grade cannabis product T1/C20 for children with autism spectrum disorder.
HERZLIYA, Israel, Sept. 13, 2019 /PRNewswire/ -- InterCure (INCR.TA), announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva Pharmaceuticals Industries (NYSE: and TASE: TEVA). Under terms of the agreement, S.L.E. will distribute Canndoc's GMP products to pharma clients, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel, including pharmacy chains. In the future, as regulatory approvals allow, S.L.E. will provide logistics capability for exporting Canndoc's products to countries that support regulations for the sale and distribution of cannabis products for medical use.